Skip to main content
Top
Published in: Hepatology International 3/2007

01-09-2007

Estimation of protein intake using urinary urea nitrogen in patients with early-stage liver cirrhosis

Authors: Yohei Kida, Hiroki Ueda, Hiroto Tanaka, Masakazu Ichinose

Published in: Hepatology International | Issue 3/2007

Login to get access

Abstract

Purpose

Evaluation of protein intake of patients with liver cirrhosis (LC) would facilitate optimal nutritional support. However, it has never been done on the basis of urinary urea nitrogen (UUN). The aim of this study, therefore, is to determine the usefulness of the estimated protein intake (EPI) based on UUN in patients with LC.

Methods

A total of 42 patients with early-stage LC were enrolled in this study. The actual protein intake (API) was defined as the dietary protein intake (1.0 g/kg/d) plus supplementation of any enteral diets containing branched-chain amino acids (BCAA). We calculated EPI from UUN using the formula [UUN (g/d) + 0.031 × body weight (kg)] × 0.625. We examined the correlation between EPI and API, the EPI/API ratio (EAR), and the correction based on the results.

Results

A significant positive correlation was found between API and EPI (r = 0.703, p < 0.001). The EAR in all patients was 0.84 ± 0.11. EPI times 1.2 was the correction needed to adjust EAR to 1. The corrected EPI was correlated with API (r = 0.704, p < 0.001). The corrected EAR of all 42 patients was 1.01 ± 0.13.

Conclusion

In conclusion, for patients with early-stage LC, an EPI calculated from UUN may be a useful tool for optimal nutritional support. The corrected EPI would be very useful for improved monitoring of early-stage LC.
Literature
1.
go back to reference Alberino F, Gatta A, Amodio P, et al. Nutrition and survival in patients with liver cirrhosis. Nutrition 2001;17:445–50.PubMedCrossRef Alberino F, Gatta A, Amodio P, et al. Nutrition and survival in patients with liver cirrhosis. Nutrition 2001;17:445–50.PubMedCrossRef
2.
go back to reference Tajika M, Kato M, Mohri H, et al. Prognostic value of energy metabolism in patients with liver cirrhosis. Nutrition 2002;18:229–34.PubMedCrossRef Tajika M, Kato M, Mohri H, et al. Prognostic value of energy metabolism in patients with liver cirrhosis. Nutrition 2002;18:229–34.PubMedCrossRef
3.
go back to reference Moriwaki H, Miwa Y, Tajika M, et al. Branched-chain amino acids as a protein- and energy-source in liver cirrhosis. Biochem Biophys Res Commum 2004;313:405–9.CrossRef Moriwaki H, Miwa Y, Tajika M, et al. Branched-chain amino acids as a protein- and energy-source in liver cirrhosis. Biochem Biophys Res Commum 2004;313:405–9.CrossRef
4.
go back to reference Selberg O, Bottcher J, Tusch G, et al. Identification of high- and low-risk patients before liver transplantation: a prospective cohort study of nutritional and metabolic in 150 patients. Hepatology 1997;25:652–7.PubMedCrossRef Selberg O, Bottcher J, Tusch G, et al. Identification of high- and low-risk patients before liver transplantation: a prospective cohort study of nutritional and metabolic in 150 patients. Hepatology 1997;25:652–7.PubMedCrossRef
5.
go back to reference Plauth M, Carbé E, Riggio O, et al. ESPEN guidelines on enteral nutrition: liver disease. Clin Nutr 2006;25:285–94.PubMedCrossRef Plauth M, Carbé E, Riggio O, et al. ESPEN guidelines on enteral nutrition: liver disease. Clin Nutr 2006;25:285–94.PubMedCrossRef
6.
go back to reference Friedman LS. Cirrhosis liver, biliary tract, & pancreas. In: Tierney LM, McPhee SJ, Paradakis MA, editors. 2006 Current medical diagnosis & treatment. 45th ed. New York: McGraw-Hill; 2005. p. 668–74. Friedman LS. Cirrhosis liver, biliary tract, & pancreas. In: Tierney LM, McPhee SJ, Paradakis MA, editors. 2006 Current medical diagnosis & treatment. 45th ed. New York: McGraw-Hill; 2005. p. 668–74.
7.
go back to reference Chung RT, Podolsky DK. Hepatic encephalopathy cirrhosis and its complication disorders of the gastrointestinal system. In: Kasper DL, Braunwald E, Fauci AS, Hauser SL, Longo DL, Jameson JL, editors. Harrison’s principles of internal medicine. 16th ed. New York: McGraw-Hill; 2005. p. 1867–9. Chung RT, Podolsky DK. Hepatic encephalopathy cirrhosis and its complication disorders of the gastrointestinal system. In: Kasper DL, Braunwald E, Fauci AS, Hauser SL, Longo DL, Jameson JL, editors. Harrison’s principles of internal medicine. 16th ed. New York: McGraw-Hill; 2005. p. 1867–9.
8.
9.
go back to reference Okamoto M, Sakaida I, Tsuchiya M. Effect of a late evening snack on the blood glucose level and energy metabolism in patients with liver cirrhosis. Hepatol Res 2003;27:45–50.PubMedCrossRef Okamoto M, Sakaida I, Tsuchiya M. Effect of a late evening snack on the blood glucose level and energy metabolism in patients with liver cirrhosis. Hepatol Res 2003;27:45–50.PubMedCrossRef
10.
go back to reference Sako K, Imamura Y, Nishimata H. Branched-chain amino acids supplements in the late evening decrease the frequency of muscle cramps with advanced hepatic cirrhosis. Hepatol Res 2003;26:327–9.PubMedCrossRef Sako K, Imamura Y, Nishimata H. Branched-chain amino acids supplements in the late evening decrease the frequency of muscle cramps with advanced hepatic cirrhosis. Hepatol Res 2003;26:327–9.PubMedCrossRef
11.
go back to reference Kawamura N, Nakajima H, Takashi SI. Administration of granulated BCAA, quality of life. Hepatol Res 2004;30S:42–45.PubMedCrossRef Kawamura N, Nakajima H, Takashi SI. Administration of granulated BCAA, quality of life. Hepatol Res 2004;30S:42–45.PubMedCrossRef
12.
go back to reference Maroni BJ, Steinman TI, Mitch WE. A method for estimating nitrogen intake of patients with chronic renal failure. Kidney Int 1985;27:58–65.PubMedCrossRef Maroni BJ, Steinman TI, Mitch WE. A method for estimating nitrogen intake of patients with chronic renal failure. Kidney Int 1985;27:58–65.PubMedCrossRef
13.
go back to reference Hellerstein MK, Munro HN. Liver cirrhosis. In: Arias IM, Boyer JI, et al. editors. The liver, biology and pathobiology. 3rd ed. New York: Raven Press; 1994. p. 1169–91. Hellerstein MK, Munro HN. Liver cirrhosis. In: Arias IM, Boyer JI, et al. editors. The liver, biology and pathobiology. 3rd ed. New York: Raven Press; 1994. p. 1169–91.
14.
go back to reference Cabre E, Gonzalez-Huix F, Abad-Lacruz A, et al. Effect of total enteral nutrition on the short-term outcome of severely malnourished cirrhotics. A randomized controlled trial. Gastroenterology 1990;98:715–20.PubMed Cabre E, Gonzalez-Huix F, Abad-Lacruz A, et al. Effect of total enteral nutrition on the short-term outcome of severely malnourished cirrhotics. A randomized controlled trial. Gastroenterology 1990;98:715–20.PubMed
15.
go back to reference Sato S, Watanabe A, Muto Y, et al. for the LIV-EN Study Group. Clinical comparison of branched-chain amino acid (l-leucine, l-isoleucine, l-valine) granules and oral nutrition for hepatic insufficiency in patients with decompensated liver cirrhosis (LIV-EN study). Hepatol Res 2005;31:232–40.PubMedCrossRef Sato S, Watanabe A, Muto Y, et al. for the LIV-EN Study Group. Clinical comparison of branched-chain amino acid (l-leucine, l-isoleucine, l-valine) granules and oral nutrition for hepatic insufficiency in patients with decompensated liver cirrhosis (LIV-EN study). Hepatol Res 2005;31:232–40.PubMedCrossRef
16.
go back to reference Marchesini G, Bianchi G, Merli M, et al. Italian BCAA Study Group. Nutritional supplementation with branched-chain amino acids in advanced cirrhosis: a double-blind, randomized trial. Gastroenterology 2003;124:1792–801.PubMedCrossRef Marchesini G, Bianchi G, Merli M, et al. Italian BCAA Study Group. Nutritional supplementation with branched-chain amino acids in advanced cirrhosis: a double-blind, randomized trial. Gastroenterology 2003;124:1792–801.PubMedCrossRef
17.
go back to reference Muto Y, Sato S, Watanabe A, et al. Effects of oral branched-chain amino acid granules on event-free survival in patients with liver cirrhosis. Clin Gastroenterol Hepatol 2005;3:705–13.PubMedCrossRef Muto Y, Sato S, Watanabe A, et al. Effects of oral branched-chain amino acid granules on event-free survival in patients with liver cirrhosis. Clin Gastroenterol Hepatol 2005;3:705–13.PubMedCrossRef
18.
go back to reference Tsuchiya M, Sakaida I, Okamoto M. The effect of a late evening snack in patients with liver cirrhosis. Hepatol Res 2005;31:95–103.PubMedCrossRef Tsuchiya M, Sakaida I, Okamoto M. The effect of a late evening snack in patients with liver cirrhosis. Hepatol Res 2005;31:95–103.PubMedCrossRef
19.
go back to reference Nishiguchi S, Habu D. Effect of oral supplementation with branched-chain amino acid granules in the early stage of cirrhosis. Hepatol Res 2004;30S:36–41.PubMedCrossRef Nishiguchi S, Habu D. Effect of oral supplementation with branched-chain amino acid granules in the early stage of cirrhosis. Hepatol Res 2004;30S:36–41.PubMedCrossRef
20.
go back to reference Suzuki K, Kato A, Iwai M. Branched-chain amino acid treatment in patients with liver cirrhosis. Hepatol Res 2004;30S:25–29.PubMedCrossRef Suzuki K, Kato A, Iwai M. Branched-chain amino acid treatment in patients with liver cirrhosis. Hepatol Res 2004;30S:25–29.PubMedCrossRef
Metadata
Title
Estimation of protein intake using urinary urea nitrogen in patients with early-stage liver cirrhosis
Authors
Yohei Kida
Hiroki Ueda
Hiroto Tanaka
Masakazu Ichinose
Publication date
01-09-2007
Publisher
Springer-Verlag
Published in
Hepatology International / Issue 3/2007
Print ISSN: 1936-0533
Electronic ISSN: 1936-0541
DOI
https://doi.org/10.1007/s12072-007-9019-0

Other articles of this Issue 3/2007

Hepatology International 3/2007 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.